Nano24

Company Overview

Snapshot

Founded in June 2020 by Prof. Nadir Arber and Dr. Shiran Shapira, Nano24 operates with 1–10 employees. The company has raised $9.5M across four funding rounds. Nano24 focuses on developing next-generation immunomodulators, with its lead product, EXO-CD24, having shown promising results in clinical trials for Acute Respiratory Distress Syndrome (ARDS).

Business overview

Nano24 is a biopharmaceutical company developing next-generation immunomodulators to address the cytokine storm, a severe complication in various pulmonary and systemic diseases. The company's core technology leverages CD24 as the drug and exosomes as the carrier, resulting in EXO-CD24, an exosomal-based drug derived from genetically manipulated human embryonic cells. This platform aims to treat unmet indications such as ARDS, sepsis, and cardiogenic shock. Nano24 is initially targeting the ARDS market, which currently lacks specific medical therapy and contributes to significant mortality rates, operating within the Health Tech & Life Sciences sector.

Strategic signal

In June 2022, Nano24 was highlighted in a news report for its research into a treatment for COVID-19 that also showed potential for other diseases. This signals the company's innovative approach to drug discovery and its ability to develop therapies with broad applicability beyond initial targets, indicating a strong potential for pipeline expansion and market impact in the biopharmaceutical industry.

Company Intelligence Q&A

What is Nano24's primary therapeutic focus?

Nano24 is focused on developing next-generation immunomodulators to treat the cytokine storm, a severe complication associated with various pulmonary and systemic diseases, with an initial focus on Acute Respiratory Distress Syndrome (ARDS).

Who founded Nano24?

Nano24 was founded in June 2020 by Prof. Nadir Arber and Dr. Shiran Shapira.

What is EXO-CD24?

EXO-CD24 is Nano24's lead product, an exosomal-based drug derived from genetically manipulated human embryonic cells, designed to act as an immunomodulator to address the cytokine storm. It has undergone clinical trials for ARDS.

Has Nano24 received any funding?

Nano24 has raised a total of $9.5M across four funding rounds.

What clinical trial progress has Nano24 made with EXO-CD24?

EXO-CD24 has completed clinical trials phases Ib+IIa and IIb, showing high success rates with no deaths caused by the cytokine storm, significantly reduced hospitalization duration, and no reported side effects.